Bone fractures, particularly tibial fractures, are a major public health concern, with non-union rates as high as 14%, leading to extended impairment and significant healthcare costs [1]. The current standard treatment for large bone defects is autologous bone grafting (ABG), which, despite its effectiveness, has limited availability and post-operative complications. Scaffold-guided bone tissue engineering (SGBTE) is a tissue engineering approach which leverages the use of 3D-printed scaffolds to guide bone tissue formation. 3D-printed scaffolds made of tricalcium silicate (Ca3Si) and medical grade polycaprolactone (mPCL) coated with calcium phosphate (CaP) have shown remarkable regenerative capabilities for treating large bone defects in preclinical models [2,3]. These scaffolds can be further combined with bone morphogenic protein 2 (BMP-2) to enhance bone formation. This study investigates the regenerative potential of 3D-printed Ca3Si-mPCL-CaP scaffolds using a 3cm tibial defect in a sheep model. Briefly, a 3cm defect was created in ten sheep tibiae and reconstructed using two experimental groups: I) Ca3Si with a mPCL-CaP mesh and II) Ca3Si + mPCL-CaP mesh + 1mg of BMP-2. The experimental groups were compared to the III) ABG and IV) mPCL scaffold control groups. After 12-months bone formation and mechanical properties were evaluated through x-rays, biomechanical testing, Micro-CT, and various microscopic and histological analyses. Results showed complete bridging of the defect after 12 months in both experimental groups, with the group receiving BMP-2 demonstrating superior mechanical properties and higher bone volumes compared to the ABG and mPCL scaffold groups. Key findings included a well-aligned collagen deposition around the Ca3Si scaffold and mPCL-CaP mesh scaffold, supporting cortical and lamellar bone formation, osteocytes in direct contact with scaffolds, along with secondary osteon formation. This study validates the potential of 3D printed Ca3Si + mPCL-CaP scaffolds as a viable alternative to the limited ABG, laying the groundwork for future clinical applications.